Lexicon Pharmaceuticals Inc [LXRX] stock is trading at $2.60, up 7.00%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LXRX shares have gain 19.82% over the last week, with a monthly amount drifted -21.69%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease. In a post published today on Yahoo Finance, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on March 07, 2023, when Jefferies initiated its Hold rating and assigned the stock a price target of $3. Previously, Piper Sandler started tracking the stock with Overweight rating on August 12, 2022, and set its price target to $10. On January 29, 2021, upgrade upgraded it’s rating to Neutral but maintained its price target of $7 on the stock. Wedbush downgraded its rating to a Neutral and increased its price target to $8 on January 29, 2021. Citigroup upgraded its rating to a Buy. Gabelli & Co upgraded its rating to Buy for this stock on November 18, 2020. In a note dated December 11, 2019, Gabelli & Co downgraded an Hold rating on this stock.
Lexicon Pharmaceuticals Inc [LXRX] stock has fluctuated between $0.92 and $3.79 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $2.60 at the most recent close of the market. An investor can expect a potential return of 284.62% based on the average LXRX price forecast.
Analyzing the LXRX fundamentals
Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] reported sales of 1.21M for the trailing twelve months, which represents a growth of 2407.14%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -142.53%, Pretax Profit Margin comes in at -145.73%, and Net Profit Margin reading is -144.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is 0.11 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.48 points at the first support level, and at 2.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.67, and for the 2nd resistance point, it is at 2.74.
Lexicon Pharmaceuticals Inc [LXRX] reported earnings per share of -$0.2 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.22/share, meaning a difference of $0.02 and a surprise factor of 9.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.21 per share as compared to estimates of -$0.21 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
For context, Lexicon Pharmaceuticals Inc’s Current Ratio is 6.92. In addition, the Quick Ratio stands at 6.91 and the Cash Ratio stands at 0.65. Considering the valuation of this stock, the price to sales ratio is 526.30, the price to book ratio is 4.58.
Transactions by insiders
Recent insider trading involved COATS LONNEL, Chief Executive Officer, that happened on Nov 16 ’23 when 90000.0 shares were purchased. Chief Executive Officer, COATS LONNEL completed a deal on Nov 10 ’23 to buy 10000.0 shares. Meanwhile, Director DEBBANE RAYMOND bought 0.15 million shares on Oct 12 ’23.
